Holen Sie sich die Stockscreener-App
2.24
0.22%
0.01
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Frontier tech research, news & data - MLQ.ai
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget
Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan
RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan
IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm
Inhibikase raises $50M to fund PAH program - TipRanks
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo
Inhibikase raises $50 million through stock sale to RA Capital - Investing.com
Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat
Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Canada
Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan
Inhibikase's $50M share sale could support Phase 3 PAH readout - Stock Titan
Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9%Here's What Happened - MarketBeat
Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn ContinuesAnnual Earnings Summary - dars.gov.et
Inhibikase Therapeutics Inc. (IKT) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
INHIBIKASE THERAPEUTICS INC (IKT) Stock Chart - ChartMill
Inhibikase Therapeutics Inc (NASDAQ: IKT) Share Price, IKT Stock News, IKT Share Price & Updates - Kalkine
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase awards stock options to 7 new hires under inducement plan - Stock Titan
Director at Inhibikase (NASDAQ: IKT) receives 155K stock options grant - Stock Titan
Inhibikase (IKT) director awarded 155,000 stock options at $1.91 exercise price - Stock Titan
Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections - Stock Titan
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Enterprise value to EBIT forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Inhibikase Therapeutics, Inc. Actuals & Estimates (NASDAQ:IKT) - TradingView
IKT Forecast — Price Target — Prediction for 2027 - TradingView
Inhibikase Therapeutics Inc (IKT) Institutional Confidence - TradingKey
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibikase Therapeutics (IKT) Holds Steady Near Support as Traders Await CatalystDividend Stock Picks - DonanımHaber
Inhibikase Therapeutics Inc (IKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibikase Therapeutics Inc (IKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibikase Therapeutics Q1 2026 Earnings: Narrower Than Expected Loss Amid Pipeline ProgressReturn On Equity - dars.gov.et
Inhibikase Therapeutics (IKT) Consolidates Near $1.67 – Key Levels in FocusTriple Bottom - newsline.com
IKT Initiates Coverage On Oppenheimer -- Rating Set to Outperfor - GuruFocus
Oppenheimer Initiates Inhibikase Therapeutics at Outperform - marketscreener.com
Inhibikase Therapeutics (IKT) Tests Support Zone After Slight DeclineFibonacci Entry Signals - newsline.com
Inhibikase Therapeutics Q1 2026 Earnings: Smaller-Than-Expected Loss on Operational UpdatesPost-Earnings Drift - dars.gov.et
Inhibikase Therapeutics (IKT) Edges Higher, Testing Key Resistance Amid Biotech Sector UncertaintyCTA Positioning - newsline.com
Inhibikase Therapeutics (IKT) Narrows Lower: Testing Key Support Near $1.61Chandelier Stop - dars.gov.et
IKT Q1 2026 Earnings: Narrow EPS Beat as Clinical Pipeline Progress ContinuesGuidance vs Actual - DonanımHaber
0.05%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):